"The immunological attributes of MAPCs make them a promising candidate for providing immunomodulatory support after organ transplantation," explained
Most other cell therapy trials have used cells of either the organ donor or recipient. However, the preparation of such customized cell therapies is costly and challenging, since it must be done one patient at a time, and can lead to inconsistent results. With this in mind, the Dahlke team decided to explore the potential of a third-party-derived MAPC to act as a universal donor. This is the approach being taken clinically by
When long-term accepted heart grafts were recovered from the MAPC-treated animals and re-transplanted into yet another group of untreated animals (genetically identical to the first group of recipients), they engrafted successfully, without triggering rejection, even when no immune suppressive drug was administered. This finding demonstrates that an immunoprivileged state, or "regional immune tolerance," had been induced in the graft that can be carried into another untreated animal.
"In the group with no treatment, the grafts were rejected in less than two weeks; short-term immunosuppressive drug treatments kept them intact just a few days longer. However, rats given a combination of short-term immunosuppressive treatment and MAPCs exhibited a high percentage of prolonged survival, even after treatment with immune suppressive drugs was stopped, indicating a promising pathway for clinical immunotherapy," Dr. Dahlke commented. "If transplantation procedures could be conducted with lower requirements for immunosuppressive drugs, this could provide a substantial benefit to patients, and could also broaden the impact of transplantation medicine, helping many more patients and providing a better quality of life."
The research effort was led by a team of renowned transplant specialists at the
"This pioneering work demonstrates that MultiStem may have broad relevance in the field of clinical transplantation by addressing several of the major hurdles that represent real challenges for patients," said Dr.
The full article, "Heart grafts tolerized through third-party Multipotent Adult Progenitor Cells can be re-transplanted to secondary hosts with no immunosuppression," can be accessed at: http://www.stemcellstm.com/content.
MultiStem cell therapy is a patented regenerative medicine product that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of multiple therapeutic factors produced in response to signals of inflammation and tissue damage. MultiStem has demonstrated therapeutic potential for the treatment of inflammatory and immune disorders, neurological conditions, and cardiovascular disease, as well as other areas, and represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. The product is extensively characterized for safety, consistency and potency. Athersys has forged strategic partnerships with Pfizer Inc. to develop MultiStem for inflammatory bowel disease and is also being evaluated as a novel therapeutic approach for certain neurological and cardiovascular conditions.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "suggest," "will," or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face that could cause actual results to differ materially from those implied by forward-looking statements are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as human therapeutics, such as the uncertainty regarding market acceptance of our product candidates and our ability to generate revenues, including MultiStem for the treatment of inflammatory bowel disease, acute myocardial infarction, stroke and other disease indications, including traumatic brain injury, and the prevention of graft-versus-host disease. These risks may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Other important factors to consider in evaluating our forward-looking statements include: our ability to raise additional capital; final results from our MultiStem clinical trials including for ischemic stroke; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials; changes in external market factors; changes in our industry's overall performance; changes in our business strategy; our ability to protect our intellectual property portfolio; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our ability to meet milestones under our collaboration agreements; our collaborators' ability to continue to fulfill their obligations under the terms of our collaboration agreements; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; and the success of our competitors and the emergence of new competitors. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: William (
B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 firstname.lastname@example.org Investor Relations: Lisa M. Wilson In-Site CommunicationsTel: (917) 543-9932 email@example.com
News Provided by Acquire Media